Understanding the Scope and Claims of United States Patent 10,189,850
Introduction
United States Patent 10,189,850, assigned to G1 Therapeutics, Inc., is a significant patent in the field of pharmaceuticals, particularly focusing on cyclin-dependent kinase (CDK) inhibitors. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Background of the Patent
The patent in question is part of a series of inventions related to CDK inhibitors, which are crucial in the treatment of various medical disorders, including cancer. The specific compound at the center of this patent is trilaciclib, also known as G1T28, which has shown promise in transiently arresting normal cells to prevent chemotherapy-induced myelosuppression[4].
Scope of the Patent
The scope of Patent 10,189,850 encompasses the synthesis, methods of use, and pharmaceutical compositions of trilaciclib. Here are some key aspects:
Compound Description
The patent describes trilaciclib as a specific N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amine compound. This compound is detailed with its chemical structure and formula, highlighting its unique properties and how it differs from other CDK inhibitors[4].
Synthetic Procedures
The patent includes detailed synthetic procedures for making trilaciclib, which are crucial for its production and use in clinical settings. These procedures are outlined in other related patents and publications, such as US 2019/135820 and WO 2020/041770[4].
Methods of Use
The patent covers the methods of using trilaciclib, particularly in the context of chemotherapy. It highlights the compound's ability to transiently protect normal cells from the adverse effects of chemotherapy, thereby improving the overall efficacy and safety of cancer treatments[4].
Claims of the Patent
The claims section of the patent is critical as it defines the legal boundaries of the invention. Here are some key claims:
Independent Claims
The patent includes independent claims that describe the compound trilaciclib, its pharmaceutical compositions, and methods of use. These claims are broad enough to cover various aspects of the invention but specific enough to distinguish it from prior art[4].
Dependent Claims
Dependent claims further specify the independent claims, often detailing specific embodiments, dosages, and methods of administration. These claims help to narrow down the scope and ensure that the patent covers all relevant aspects of the invention[4].
Patent Landscape
Understanding the patent landscape is essential for navigating the intellectual property rights surrounding CDK inhibitors.
Related Patents
Patent 10,189,850 is part of a family of patents related to CDK inhibitors. Other patents, such as U.S. Pat. Nos. 8,598,186; 8,598,197; 9,957,276, and 10,189,849, also assigned to G1 Therapeutics, Inc., cover various aspects of these compounds and their uses[4].
Global Patent Family
The patent family for trilaciclib includes international patents and applications, such as those filed under the World Intellectual Property Organization (WIPO) and in various national patent offices. This global coverage is crucial for protecting the invention worldwide[4].
Searching and Analyzing Patents
To conduct a thorough analysis of Patent 10,189,850, one can use several resources provided by the USPTO:
Patent Public Search
The Patent Public Search tool is a powerful resource for searching prior art and related patents. It offers modern interfaces and enhanced access to prior art, which can help in understanding the broader patent landscape[1].
Global Dossier
The Global Dossier service allows users to view the file histories of related applications from participating IP Offices, including the IP5 Offices. This service is particularly useful for analyzing the global patent family and understanding the status of related applications[1].
Common Citation Document (CCD)
The CCD application provides a single point of access to citation data relating to the patent applications of the IP5 Offices. This helps in visualizing the prior art cited by multiple offices for the same invention[1].
Economic and Legal Implications
The economic and legal implications of Patent 10,189,850 are significant.
Market Impact
CDK inhibitors like trilaciclib have the potential to revolutionize cancer treatment by reducing the side effects of chemotherapy. This can lead to improved patient outcomes and significant market opportunities for G1 Therapeutics, Inc.[4].
Legal Considerations
The legal landscape for small claims patent courts, as studied by the Administrative Conference of the United States (ACUS), could impact how disputes related to this patent are handled. A small claims patent court could provide a more streamlined and cost-effective way to resolve patent disputes[5].
Key Takeaways
- Compound and Synthesis: Patent 10,189,850 covers the compound trilaciclib, its synthesis, and methods of use.
- Claims: The patent includes independent and dependent claims that define the scope of the invention.
- Patent Landscape: The patent is part of a broader family of patents related to CDK inhibitors, with global coverage.
- Search and Analysis Tools: Resources like Patent Public Search, Global Dossier, and CCD are essential for analyzing the patent and its context.
- Economic and Legal Implications: The patent has significant market and legal implications, including potential impacts from small claims patent courts.
FAQs
Q: What is the main compound described in Patent 10,189,850?
A: The main compound is trilaciclib, also known as G1T28, a cyclin-dependent kinase inhibitor.
Q: How does trilaciclib work in cancer treatment?
A: Trilaciclib transiently arrests normal cells to prevent chemotherapy-induced myelosuppression, improving the safety and efficacy of cancer treatments.
Q: What resources can be used to search and analyze patents related to this invention?
A: Resources include the Patent Public Search tool, Global Dossier, and the Common Citation Document (CCD) application.
Q: What are the economic implications of this patent?
A: The patent has significant market potential by improving cancer treatment outcomes and reducing side effects of chemotherapy.
Q: How might a small claims patent court impact disputes related to this patent?
A: A small claims patent court could provide a more streamlined and cost-effective way to resolve patent disputes, potentially affecting how G1 Therapeutics, Inc. manages its intellectual property.
Sources
- USPTO - Search for patents. Retrieved from https://www.uspto.gov/patents/search
- U.S. Patent and Trademark Office (USPTO) | USAGov. Retrieved from https://www.usa.gov/agencies/u-s-patent-and-trademark-office
- Patent Claims Research Dataset - USPTO. Retrieved from https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
- US Patent for Morphic forms of trilaciclib and methods of .... Retrieved from https://patents.justia.com/patent/12168666
- U.S. Patent Small Claims Court. Retrieved from https://www.acus.gov/research-projects/us-patent-small-claims-court
